Cargando…

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer

INTRODUCTION: Immunochemotherapy using PD-1/PD-L1 antibodies in combination with chemotherapeutic agents has become a mainstream treatment for cancer patients, but it remains unclear which drug combinations would produce best therapeutic outcome. OBJECTIVES: The purpose of this study was to investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glorieux, Christophe, Xia, Xiaojun, You, Xin, Wang, Zining, Han, Yi, Yang, Jing, Noppe, Gauthier, Meester, Christophe de, Ling, Jianhua, Robert, Annie, Zhang, Hui, Li, Sheng-Ping, Wang, Huamin, Chiao, Paul J., Zhang, Li, Li, Xiaobing, Huang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481954/ https://www.ncbi.nlm.nih.gov/pubmed/36100320 http://dx.doi.org/10.1016/j.jare.2021.12.005

Ejemplares similares

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
por: Glorieux, Christophe, et al.
Publicado: (2020)

Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells
por: Glorieux, Christophe, et al.
Publicado: (2019)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

Extracellular vesicles derived from fibroblasts induced with or without high glucose exert opposite effects on wound healing and angiogenesis
por: Bian, Xiaowei, et al.
Publicado: (2022)

PLA2G2A Phospholipase Promotes Fatty Acid Synthesis and Energy Metabolism in Pancreatic Cancer Cells with K-ras Mutation
por: Zhang, Mingquan, et al.
Publicado: (2022)

Curvature increases permeability of the plasma membrane for ions, water and the anti-cancer drugs cisplatin and gemcitabine
por: Yesylevskyy, Semen, et al.
Publicado: (2019)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Cisplatin/gemcitabine: Pancytopenia: case report
Publicado: (2021)

Oncogenic K-ras Induces Mitochondrial OPA3 Expression to Promote Energy Metabolism in Pancreatic Cancer Cells
por: Meng, Ning, et al.
Publicado: (2019)

Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma
por: Li, Qiongxuan, et al.
Publicado: (2018)

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2019)

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma
por: Li, Xiao‐Min, et al.
Publicado: (2022)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
por: Rajan, Narayan, et al.
Publicado: (2014)

ELK4 exerts opposite roles in cytokine/chemokine production and degranulation in activated mast cells
por: Huang, Yuji, et al.
Publicado: (2023)

First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis
por: Chang, Zhe, et al.
Publicado: (2014)

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens
por: Zheng, Li, et al.
Publicado: (2018)

Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1
por: Posada, Itziar M. D., et al.
Publicado: (2017)

Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma
por: Suksawat, Manida, et al.
Publicado: (2022)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Urotensin II and urantide exert opposite effects on the cellular components of atherosclerotic plaque in hypercholesterolemic rabbits
por: Yu, Qing-qing, et al.
Publicado: (2019)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

RasGAP-derived peptide GAP159 enhances cisplatin-induced cytotoxicity and apoptosis in HCT116 cells
por: Zhang, Hao, et al.
Publicado: (2014)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
por: Liu, Xiangli, et al.
Publicado: (2019)

Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma
por: Liu, Jian-Ye, et al.
Publicado: (2013)

Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity
por: Luo, Yang, et al.
Publicado: (2015)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Different gap junction-propagated effects on cisplatin transfer result in opposite responses to cisplatin in normal cells versus tumor cells
por: Zhang, Yuan, et al.
Publicado: (2015)

Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations
por: Li, Jing, et al.
Publicado: (2016)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
por: Ozkaya, Sevket, et al.
Publicado: (2008)

Cisplatin/gemcitabine: Lack of efficacy in lung adenocarcinoma: case report
Publicado: (2021)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

Alternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma progression
por: Shao, Ying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i4977daqgc2g4nim7uges96e4s